Subsequent percutaneous breast biopsies after initial atypia diagnosis: The patient burden of long-term follow up - 13/12/24

Abstract |
Background |
Breast atypia increases overall breast cancer risk, potentially necessitating future interventions. This study examines the frequency and outcomes of additional percutaneous biopsies after an atypia diagnosis.
Methods |
Adult patients with breast atypia (atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ) at a single institution were reviewed for subsequent core needle biopsies (CNBs) and corresponding malignant outcomes.
Results |
Among 432 patients, median age at diagnosis was 54.8 y. Seventy-one (71/432, 16.4 %) patients developed a breast malignancy. During a median follow-up of 7.4 y, 113 patients underwent 149 additional CNBs. Twenty-six patients (26/113, 23.0 %) had >2 additional CNBs. Approximately half (79/149, 53.0 %) of all additional CNBs occurred within 5 years after breast atypia diagnosis.
Conclusion |
A considerable number of patients with breast atypia undergo additional percutaneous biopsies, especially within 5 years post-atypia diagnosis. Our study highlights the significant burden of surveillance and the need for tailored follow-up strategies.
Le texte complet de cet article est disponible en PDF.Highlights |
• | ∼25 % of patients with breast atypia underwent ≥1 additional CNB. |
• | Atypia type (ADH, ALH, LCIS) was not associated with additional CNBs. |
• | Most additional CNBs (64 %) occur within 5 years of an atypia diagnosis. |
Keywords : Breast atypia, Percutaneous biopsy, Core-needle biopsy, Atypical ductal hyperplasia, Atypical lobular hyperplasia, Lobular carcinoma in-situ
Plan
Vol 239
Article 115993- janvier 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
